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1 INTRODUCTION 
 
Chronic Kidney Disease is a process with multiple etiologies, resulting 
in a continuous decrease of nephron number and function leading to end stage 
renal disease. 
End stage renal disease is a clinical condition in which there is an 
irreversible loss of renal function rendering the patient to depend permanently 
on renal replacement therapy (Dialysis or Transplantation).1 
Chronic kidney disease is the most debilitating condition because of its 
significant morbidity and mortality. The prevalence of chronic kidney disease 
is important in planning the care of patients afflicted by it. 
The prevalence of chronic renal failure in Indian adult population is 
0.78% (~7.85 million Chronic renal failure patients in 1 billion population).2 
The prevalence of patients with end stage renal disease in India is 
120/million population.3 
The prevalence of patients on dialysis in India is 100/million 
population.4 
The National Kidney Foundation / Dialysis Outcome Quality Initiative5 
has defined chronic kidney disease as “either kidney damage (or) GFR <60 
mL/min/1.73 m2 for atleast 3 months”. Kidney damage is defined as  
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“Pathologic abnormalities or markers of damage including abnormalities in 
blood (or) urine tests (or) imaging studies. 
The goal of hemodialysis in patients with chronic kidney disease is to 
restore the composition of the internal environment, by diffusional transfer of 
the solutes along the concentration gradient between the dialysis fluid and 
blood. This corrects the concentration of various solutes that were initially 
altered in patients with chronic kidney disease.6 Dialysis causes changes in the 
plasma concentration of trace elements in blood, which are the essential 
nutrients of human beings with a gamut of functions. 
The trace elements are components of many enzymes with regulatory, 
immunologic and antioxidant functions. Trace element disturbances in uremic 
patients occur due to reduced renal function, proteinuria leading to loss of 
protein bound elements (Zinc and Copper) and alterations in gastrointestinal 
absorption. Trace element disturbances in patients on hemodialysis occur 
depending on the concentration gradient between the ultrafiltrable amount of an 
element in serum and its concentration in the dialysis fluid. Some trace 
elements may be removed leading to deficiency where as others present as 
contaminant in the dialysis fluid could be transferred to patients leading to 
toxicity. 
A survey of yearly statistics of patients undergoing hemodialysis in 
Nephrology department of Stanley Medical College Hospital shows that the 
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number has increased significantly over the past 6 years (i.e. 1086 patients in 
the year 2000 to 2824 patients in the year 2006). As the number of patients on 
hemodialysis increases, the incidence of complications arising out of it can also 
increase. Trace element disturbances that are found associated with long term 
hemodialysis should be treated to improve the quality and longevity of 
patient’s life. 
This study was undertaken to evaluate the status of trace elements 
namely- Zinc, Copper and Iron, and their metabolism in patients, who were on 
long-term hemodialysis.  
4 AIM AND OBJECTIVE 
The aim of this study is to determine the trace element status in patients 
with end stage renal disease undergoing long-term hemodialysis in the 
Nephrology department of Stanley Medical College hospital. 
The objectives of this study is -  
¾ To determine the indicators of iron metabolism such as serum iron, TIBC, 
ferritin, transferrin saturation and transferrin in patients on long-term 
hemodialysis. 
¾ To determine the metabolic indicators of copper – serum copper and 
ceruloplasmin, and to determine the serum zinc levels in patients on      
long-term hemodialysis. 
¾ To correlate the relationship between serum iron with copper and zinc in 
patients on long-term hemodialysis. 
5 REVIEW OF LITERATURE 
The kidneys play a central role in homeostatic mechanisms of human 
body and reduced renal function strongly correlates with increased morbidity 
and mortality. 
Chronic kidney disease is the progressive loss of renal function over 
months to years leading to end stage renal disease. Without dialysis or 
transplantation, the mortality associated with end stage renal disease is 100%7. 
Uremia is a syndrome that reflects dysfunction of multiple organs as a result of 
untreated or undertreated acute or chronic renal failure1. 
EPIDEMIOLOGY: 
Worldwide, over 1 million people are alive on dialysis or with a 
functioning graft8. Throughout the world, chronic kidney disease is a growing 
health problem because of its increasing prevalence, incidence and dismal 
outcomes. 
The US Renal Data System9 has reported more than 76,500 deaths in 
patients with end stage renal disease in the year 2001,an annual mortality rate 
in excess of 20%. This figure has remained unchanged for a decade. 
The prevalence of end stage renal disease in South-east Asia is 80-96 
cases per million-population4. Primary Glomerulonephritis is the most common 
cause of end stage renal disease worldwide. 
6 
Diabetic Nephropathy is a major cause of end stage renal disease and its 
prevalence in India is 26.8%4. Every patient undergoing dialysis has a mean of 
four co-morbid conditions; about 15 hospital days per year and a self-reported 
quality of life lower than that of general population9. The incidence11 of various 
causes of ESRD is given in figure No.1. 
 RISK FACTORS FOR CHRONIC KIDNEY DISEASE:    
The risk factors1 of chronic kidney disease are as follows. 
¾ Family history of heritable renal disease 
¾ Hypertension 
¾ Diabetes mellitus 
¾ Autoimmune disease 
¾ Past episode of acute renal failure 
¾ Current evidence of kidney damage with normal or even increased 
glomerular filtration rate 
 ETIOLOGY OF CHRONIC KIDNEY DISEASE: 
¾ Developmental/congenital conditions:12 
• Renal agenesis 
• Aplastic kidneys 
• Renal hypoplasia 
• Ectopic /displaced kidneys 
• Fused kidneys 
7 
¾ Genetic causes (Monogenic inheritance) 
• Polycystic  kidney disease 
• Medullary cystic disease 
• Alport’s hereditary nephritis 
• Nephronopthisis 
• Fabry’s disease 
¾  Neoplasms: 
• Benign and Malignant tumors of kidney 
•  Wilm’s tumor 
¾   Infections: 
• Recurrent Pyelonephritis 
• Renal Tuberculosis 
• Post- streptococcal glomerulonephritis 
¾   Systemic conditions: 
• Diabetes mellitus 
• Hypertension  
• Gout 
• Hepato-renal syndrome 
• Amyloidosis 
• Scleroderma 
• Good Pasteur syndrome 
• Systemic lupus erythematosis 
8 
PATHOPHYSIOLOGY OF CHRONIC KIDNEY DISEASE: 
The pathophysiology1 involves 
¾ Initiating mechanisms specific to the underlying etiology.                                   
¾ Progressive mechanisms following long term reduction of renal 
mass, irrespective of etiology, characterized by tubular atrophy,             
glomerulo-sclerosis, interstitial fibrosis and interstitial mononuclear cellular 
infiltrates.                                                                                  
The reduction in renal mass is compensated by structural and functional 
hypertrophy of surviving nephrons. Vasoactive molecules such as cytokines 
and growth factors mediate this compensatory hypertrophy. It is initially due to 
adaptive hyperfiltration, mediated by increase in glomerular capillary pressure 
and flow. The renal function remains relatively normal through these processes, 
until 75%-80% of the nephrons are damaged and non-functional. These 
adaptations are short lived, in that they predispose to sclerosis of the remaining 
viable nephron population. Increased intrarenal activity of renin-angiotensin 
axis appears to contribute both initial adaptive hyperfiltration and to the 
subsequent maladaptive hypertrophy and sclerosis. 
STAGES OF CHRONIC KIDNEY DISEASE: 
Chronic kidney disease is classified into five stages based on glomerular 
filtration rate and is shown in Table No.1 (Refer Opposite page). 
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UREMIA: 
It is a clinical syndrome that occurs due to profound loss of renal    
function, resulting in retention of urea and other end products of metabolism, 
normally excreted in urine. The most common toxins in uremia are the          
by-products of protein and aminoacid metabolism. The uremic solutes14 with 
potential toxicity are given below. 
 UREMIC TOXINS  
¾ Urea 
¾ Guanidines: 
• Methyl guanidine, Guanidinosuccinic acid, Creatinine, 
Creatine 
¾ Phenols: 
• O-Cresol, P-Cresol, Benzyl alcohol 
¾ Hippurates: 
• P-hydroxy hippurate 
¾ Phenolic acid: 
• P- hydroxy phenyl acetic acid 
¾ Benzoates 
¾ Polypeptides: 
• Beta-2 micro globulin 
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¾ Indoles: 
• Indol-3 acetic acid and Indoxy sulfate 
¾ Middle molecules: 
• Ammonia, Alkaloids, Uric acid, Myoinositol, Oxalate 
¾ Hormones: 
• Parathyroid hormone, Natriuretic factor, Glucagon, Growth               
hormone, Gastrin 
¾ Xanthine, Hypoxanthine 
¾ Amines: 
• Putrescine, Spermine, Spermidine. 
¾ Endorphins 
¾ Pseudouridine 
Uremia involves defective renal excretory, metabolic and endocrine 
functions. It is accompanied by anemia, malnutrition, impaired metabolism of 
carbohydrates, fats and proteins, and defective utilization of energy15. The 
clinical abnormalities of uremia are listed below. 
CLINICAL ABNORMALITIES IN UREMIA: 
The clinical abnormalities15 in uremia are given below. 
1. Fluid and Electrolyte disturbances: 
• Volume expansion and contraction 
• Hypernatremia and hyponatremia 
• Hyperkalemia and hypokalemia 
11
 • Metabolic acidosis 
• Hyperphosphatemia 
• Hypocalcemia 
2. Endocrine – metabolic disturbances: 
• Secondary hyperparathyroidism 
• Carbohydrate intolerance 
• Hyperuricemia 
• Hypertriglyceridemia 
• Protein-calorie malnutrition 
• Infertility and sexual dysfunction 
• Amenorrhoea 
• Hypothermia 
3. Neuro muscular disturbances: 
• Fatigue 
• Headache 
• Sleep disturbances 
• Peripheral neuropathy 
4. Cardiovascular and pulmonary disturbances: 
• Congestive cardiac failure (or) Pulmonary edema 
• Pericarditis 
• Uremic lung 
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5. Dermatologic disturbances: 
• Pallor and Ecchymoses   
6. Gastrointestinal disturbances: 
• Anorexia, nausea and vomiting 
• Gastroenteritis 
7.  Hematologic and immunologic disturbances: 
• Normocytic and normochromic anemia 
• Increased susceptibility to infection 
 
RENAL REPLACEMENT THERAPY: 
Renal replacement therapy16 includes dialysis procedures such as                 
¾ Hemodialysis 
¾ Peritoneal dialysis 
¾ Continuous hemofiltration 
¾ Continuous hemodiafiltration 
 Kidney transplantation has become an effective form of renal 
replacement therapy. 
History of Dialysis: 
           In 1861, Thomas Graham Bell in Glasgow, Scotland, carried out the first 
dialysis experiments separating crystalloids and colloids in a solution. He 
coined the term “Dialysis”.16 The first human dialysis was performed by Georg 
Haas from Gieben, Germany using large celloidin tubes mounted in glass 
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containers. In 1943, Willem Kolff at the Groningen University Hospital, 
introduced the first dialyser suitable for use in man17. 
Definition of Dialysis:  
      Dialysis is the process of separating macromolecules from ions and low 
molecular weight compounds in solution, by the difference in their rates of 
diffusion through a semi-permeable membrane, through which crystalloids can 
pass readily but colloids pass very slowly (or) not at all16. Hemodialysis 
equipment consists of blood delivery system, the composition and delivery 
system of the dialysate and the dialyser as shown in figure No.218.  
  Hemodialysis is the most common method used to treat patients with 
advanced and permanent kidney failure, unsuitable for other modalities of 
treatment such as peritoneal dialysis and kidney transplantation. 
PRINCIPLE OF HEMODIALYSIS: 
A constant flow of blood on one side of a semi-permeable membrane 
and a cleansing solution (dialysate – a fluid with osmotically balanced solution 
of electrolytes, buffer and glucose in water) on the other, allows removal of 
waste products by diffusive and convective transport.19 
The driving force for diffusion is the concentration gradient between the 
blood and dialysate, which is maintained by countercurrent flows and high flow 
rates. Excess water from the patient’s blood can be removed by manipulating 
the negative hydrostatic pressure on the dialysate side of the system by a 
process called Ultra filtration.  
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COMPLICATIONS OF HEMODIALYSIS: 
 
¾ Cardiovascular diseases    -     Coronary artery disease (40%)  20,21 
 
         Left ventricular hypertrophy (75%) 
 
¾ Hypertension 
 
¾ Dialysis Amyloid 
 
¾ Malnutrition 
 
¾ Vascular calcification 
 
¾ Trace element disturbances 
 
 
A large number of studies have indicated that the concentration of trace 
elements is altered in patients undergoing hemodialysis. 
 Muirhead N, Kertesz A et al22 had studied the Zinc metabolism in patients 
on maintanence hemodialysis and evaluated the prevalence of zinc 
deficiency and abnormalities of zinc metabolism in patients with end stage 
renal disease. 
 Hosokawa S, Nishitani H et al23 reported serum copper concentration 
levels in chronic hemodialysis patients. They observed that there was a 
significant increase in serum copper in patients undergoing hemodialysis, 
and they found no significant correlation between serum copper and red 
blood cell count, hematocrit, hemoglobin and serum iron levels. 
 Hung KY, Ho CY et al24 reported trace element burden in geriatric 
patients and found decreased plasma zinc and increased plasma copper 
concentrations in hemodialysis patients. 
15
 TRACE ELEMENTS 
 
It has been known for long that minerals perform specific functions in 
the human system and are essential to human beings. They are classified based 
on their requirement to humans as macro and micro minerals. The micro 
minerals are also known as trace elements. Trace elements are those that occur 
in human and animal tissues in mg/kg amounts or less and in µg/dL in body 
fluids. Ultra trace elements are those that are found at ng/dL (or) µg/kg.25 
A trace element is considered to be essential, when the signs and 
symptoms induced by a deficient diet is reversed by an adequate supply of the 
trace element under investigation. Essential trace elements include Iron, 
Copper, Zinc, Cobalt, Iodine, Selenium, Molybdenum, Chromium, Boron, 
Manganese, Nickel, Silicon, Vanadium and Fluorine. 
 
IRON 
Iron is the fourth most common element on the planet. It is involved in 
many important biochemical reactions, and is recognized as an essential 
nutrient for living organisms. At birth, infants acquire about 350mg of iron 
from their mothers.26 This iron is distributed into various compartments in the 
body. After birth, iron balance is maintained by gastrointestinal absorption 
from diet.27,28 There is no physiological mechanism of iron excretion. 
Obligatory losses (1-2mg/dL) result from shedding of epithelial cells from 
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intestinal and urinary tracts, from desquamation of skin, and from menstruation 
by women in their child-bearing years.28,29 
SOURCES: 
Heme and non-heme iron from animal and plant sources respectively, 
are the two main sources of iron .The foods rich in heme and non-heme iron are 
enumerated in Table No.2 (Refer Opposite Page). 
DAILY REQUIREMENTS OF IRON: 
The recommended daily intake of iron is given in Table No.2(a) (Refer 
Opposite page). 
ABSORPTION: 
 Iron is absorbed mainly in the enterocytes of duodenum and proximal 
jejunum as shown in Figure No.330. Of the iron absorbed, 25% is heme iron and 
only 5% is non-heme iron. Non-heme iron present mostly in ferric form is 
ionized by gastric juice and reduced by Ferrireductase to the more soluble 
ferrous state in which form iron is absorbed. Vitamin C in food also favors 
reduction of ferric iron to ferrous iron. The transfer of iron from the apical 
surfaces of enterocytes into their interior is performed by a proton-coupled 
divalent metal transporter (DMT 1). Heme is transported into the enterocytes 
by heme transporter (HT), and heme oxidase (HO) releases Fe2+ from the 
heme. Inside the enterocytes, iron can either be stored as ferritin or transferred 
across the basolateral membrane by another protein, iron regulatory protein 
(IREG1) (or) ferroportin –1 into the plasma, where it is carried by transferrin. 
Ferroportin-1 interacts with the copper-containing protein hephaestin (HP), 
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which is similar to ceruloplasmin, having ferroxidase activity that oxidizes 
ferrous ion to ferric ion, the form in which iron is transported in the plasma by 
transferrin to other tissues. Regulation of iron balance involves a 25-aminoacid 
peptide, Hepcidin (Hep – hepatocyte, Cidin – bactericidal protein), synthesized 
in the liver. Hepcidin synthesis increases in response to iron overload and is 
decreased in iron deficiency. Hepcidin binds ferroportin-1 and induces its 
internalization and lysosomal degradation preventing iron efflux from 
enterocytes and reticuloendothelial / hepatic macrophages to the plasma31.   
The compartments of iron in our body are given in Table No.3 (Refer Opposite 
Page). 
TRANSFERRIN: 
A plasma iron transport protein - apotransferrin, binds the iron absorbed 
from the intestine or released from catabolism of hemoglobin. This iron is then 
transported to storage sites such as liver and reticuloendothelial system, and to 
erythropoietic tissue for hemoglobin synthesis. 
Apotransferrin is a β1 – globulin with a molecular of 75,000 Da, having 
two binding sites for ferric iron per molecule. The apotransferrin-Fe3+ complex 
is called transferrin. 
Transferrin consists of a single polypeptide chain and two homologous 
domains, each containing a Fe3+ binding site. Transferrin is synthesized mainly 
in liver and choroid plexus of brain. Transferrin has a half-life of about 8 – 10 
days. Transferrin reversibly binds many polycations - iron, copper, zinc, cobalt 
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and calcium. Based on the transferrin concentration of 3mg/mL of plasma, the 
total transferrin bound iron in the body is about 3mg. (Table No.3) 
 
IRON UPTAKE BY CELLS: 
Transferrin is recognized by specific cell membrane transferrin receptors 
present in all nucleated cells especially in erythroid precursors, placenta, liver, 
neoplastic tissue, and rapidly dividing normal cells.33 The receptor can bind 
two molecules of transferrin. The affinity of receptor for its ligand depends on 
both the iron content of transferrin and the pH. Transferrin binds to the 
receptors on the cell membrane and is internalized enclosed within the 
endocytic vesicles. Iron is then released from transferrin due to acid pH inside 
the vesicle. Once released, ferric form is reduced to ferrous form and 
incorporated into ferritin and hemosiderin, and used for the synthesis of 
compounds such as, hemoglobin, myoglobin and cytochromes. The receptor – 
apotransferrin complex is recycled to cell surface where the apotransferrin is 
released and recycled, making the receptor available again for binding. 
STORAGE IRON: 
 
         Iron is stored in our body in the form of ferritin and hemosiderin. In 
hepatocytes, macrophages of bone marrow and other organs, ferritin provides a 
reserve of iron readily available for formation of hemoglobin and other heme 
proteins. Thus iron is shielded from body fluids, so that it is unable to produce 
oxidative damage, as would be the case if it were in ionic form. 
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        Ferritin consists of an apoferritin shell and an interior ferric-oxyhydroxide 
(FeOOH)X crystalline core. The apoferritin shell consists of 24 subunits, which 
are either L (light) or H (heavy) ferritin chains. The proportion of light to heavy 
chains differs from tissue to tissue as shown in figure No.4.34 
Only ferrous iron is taken up by ferritin, and a catalytic site on the H 
chain oxidizes it to ferric form. Iron is released from ferritin nonenzymatically 
by reduced flavin mononucleotide and other reducing substances. 
Ferritin is present in the blood in very low concentration. The circulating 
form differs from tissue ferritin in that it is glycosylated, contains mostly L 
chains, and is poor in iron, representing mostly apoferritin. The plasma ferritin 
concentration declines very early in the development of iron deficiency, long 
before changes are observed in blood hemoglobin concentration, red blood cell 
size and serum iron concentration. 
 
HEMOSIDERIN: 
 
Hemosiderin is an amorphous water-soluble compound formed by 
aggregated and partial deproteinised ferritin. It is found predominantly in cells 
of the liver, spleen and bone marrow. Iron is released slowly from hemosiderin 
because it occurs in relatively large aggregates and therefore has a much 
smaller surface/volume ratio. 
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CLINICAL SIGNIFICANCE OF SERUM IRON, TIBC, TRANSFERRIN, 
TRANSFERRIN SATURATION AND FERRITIN: 
 
SERUM IRON: 
 
The serum iron concentration refers to the iron bound to transferrin and 
does not include the iron in free hemoglobin. There is a diurnal variation with a 
fall in iron concentration in evening. Significant day-to-day variation occurs as 
well35. The conditions that affect serum iron concentration have been enlisted 
in the Table No.4 (Refer Opposite Page). Moreover for proper interpretation of 
serum iron, the levels of total iron binding capacity (TIBC) and transferrin 
saturation are also necessary.  
TOTAL IRON BINDING CAPACITY: 
 Normally only one third of transferrin is bound with iron. Thus serum 
transferrin has considerable reserve iron binding capacity. This is called the 
serum unsaturated iron binding capacity (UIBC). The TIBC is a measurement 
of maximum concentration of iron that transferrin can bind and is therefore an 
indirect way of assessing transferrin level. Serum transferrin concentration can 
be estimated from TIBC by the following relationship36. 
 Serum transferrin  (mg/dL) = 0.70 Χ TIBC  (µg/dL) 
(or) 
TIBC  (µg/dL) = 1.43 x Transferrin  (mg/ dL) 
The clinical significance of Serum transferrin and TIBC are given in 
Table No.5 (Refer Opposite Page). 
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SERUM TRANSFERRIN SATURATION: 
Transferrin saturation indicates the iron readily available for 
erythropoiesis. Transferrin saturation is calculated from serum iron and TIBC 
as follows37. 
 
            Serum iron 
Transferrin Saturation (%)   =    --------------------     X    100 
                 TIBC 
   
Clinical conditions associated with changes in transferrin saturation are 
enlisted in Table No.6 (Refer Opposite Page). 
 
SERUM FERRITIN: 
The measurement of serum ferritin provides the most useful indirect 
estimate of the body iron stores.38,39 However ferritin is an acute phase 
reactant37. Hence in fever, acute infections, rheumatoid arthritis and chronic 
inflammatory disorders, ferritin is found to be elevated. The clinical conditions 
associated with changes in serum ferritin are enumerated in the                  
Table No.7 (Refer Opposite Page).                     
Among the biochemical markers mentioned above, serum ferritin has 
been found to be the most reliable parameter for assessment of body iron status 
as it is least influenced by extraneous factors. 38,39,40,41    
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IRON DEFICIENCY IN CHRONIC KIDNEY DISEASE PATIENTS ON 
HEMODIALYSIS:  
 
           Currently, the 2 best tests of iron status of chronic kidney disease 
patients on hemodialysis are percent transferrin saturation and serum ferritin.  
In normal healthy persons, iron deficiency is considered absolute, when iron 
stores are depleted, as indicated by serum ferritin <12 ng/mL, and iron delivery 
to erythroid marrow is impaired, as evidenced by transferrin saturation <15%. 
          Absolute iron deficiency in chronic kidney disease patients has been 
defined as serum ferritin <100 ng/mL and transferrin saturation <20%.         
Iron deficiency is common in patients on hemodialysis due to blood loss in the 
dialyser tubing and the dialyser, frequent blood sampling and gastrointestinal 
blood losses that cannot be compensated for by sufficient absorption of iron 
from the gastrointestinal tract.42        
23
 ZINC 
Zinc is the second most abundant trace element in the body next to iron. 
Zn2+ with atomic number 30 and atomic weight 65.39 has a filled 3d electron 
shell and is a stable ion. Zinc is a good electron acceptor (strong Lewis acid) 
with no redox reactions. Zinc is known to be essential for growth and 
development of all organisms. 
DIETARY SOURCES: 
Zinc is widely distributed in foods mainly bound to proteins. Red meat 
and fish are rich in zinc. Wheat germ and whole bran are good sources but 
milling and food processing reduce their zinc content. 
DAILY REQUIREMENTS:    
The daily requirements of zinc are given in the Table No.8 (Refer 
Opposite Page). 
ABSORPTION, TRANSPORT AND METABOLISM: 
About 30 % ± 10 % of dietary zinc is absorbed in the small intestine, as 
estimated by double isotopic tracer ratio method.44 Absorption of Zn in the 
small intestine is decreased by phytates, phosphates, calcium, iron, copper, 
dietary fiber and a constituent of beans.45,46 Absorption is increased by glucose, 
aminoacids and peptides . 
Absorbed zinc is transported to the liver by portal circulation, where 
active incorporation into metalloenzymes and plasma proteins occurs.             
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In the circulation, zinc is 80% bound to albumin and most of the rest is bound 
to alpha-2 macroglobulin.47 
Total adult body zinc is 2 to 2.5g and the metal is present in cells of all 
metabolically active tissues and organs. About 55% of the total is found in 
muscle and about 30% in bone.45 The prostate, semen and retina have high 
local concentration of zinc. In RBC’s, zinc in the form of carbonic anhydrase is 
about 10 times more concentrated than plasma. 
Zinc is excreted in both feces and urine. Fecal excretion includes both 
unabsorbed dietary zinc and zinc resecreted into the gut from pancreatic fluid 
and other intestinal fluids.48 Urinary excretion of zinc is about 0.5 mg/day. Zinc 
excretion is markedly increased in catabolic process such as post-operative 
states and in starvation as a result of release from skeletal muscle.49 
 FUNCTIONS OF ZINC: 
Zinc is an essential constituent of all six classes of enzymes as well as 
transcription and replication factors.50,51 Important examples include carbonic 
anhydrase, alkaline phosphatase, alcohol dehydrogenase, RNA and DNA 
polymerase, thymidine kinase and superoxide dismutase.52  Zinc fingers53,54 are 
biologically active molecules that play a role in gene expression by acting as 
DNA binding transcription factors and play a key role in developmental 
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biology and also in the regulation of steroid, thyroid and other hormone 
synthesis. 
Zinc is essential for normal spermatogenesis, sperm physiology, and 
normal embryonic development and is essential for formation and function of 
the immune system. Zinc also plays a role in the sense of taste and in wound 
healing.55 
DEFICIENCY OF ZINC: 
Fasting morning plasma zinc less than 30 µg/dL suggests likely 
deficiency of zinc56. The clinical presentation of deficiency disease is varied, 
non-specific, and related to the degree and duration of the depletion.48,57,58 
Disorders of zinc deficiency includes growth retardation, alopecia, 
acrodermatitis, diarrhoea, immunologic dysfunction, failure to thrive, 
psychological disturbances, gonadal atrophy, impaired spermatogenesis and 
congenital malformations.55 
ZINC IN RENAL FAILURE: 
Urinary zinc excretion varies from 375±150 µg/dL to 643±198 µg/dL.    
The zincuria is due either to displacement from protein or to competition 
between zinc and the aminoacids for tubular reabsorption. 
Patients with renal failure ingesting low protein diet and with marked 
proteinuria develop low plasma zinc levels. Patients undergoing hemodialysis 
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on ferrous sulphate tablets results in malabsorption of zinc. Some hemodialysis 
patients have high zinc levels due to the use of either zinc oxide plasters that 
bind the coils of artificial kidney, or to higher zinc content in the dialysate as a 
result of galvanized iron used in hemodialysis tank.59 
LABORATORY ASSESSMENT OF ZINC STATUS  
PLASMA ZINC:  
Plasma zinc concentrations exhibit both circadian and postprandial 
fluctuations. Zinc levels decrease after food and are higher in the morning than 
in the evening. Serum zinc levels are 5% to 15% higher than plasma levels 
because of osmotic fluids shift from the blood cells when various 
anticoagulants are used.56 
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 COPPER 
Copper was one of the first metals known to man, used probably 
between 8000 and 7000 BC. The word copper derives from the Latin 
’Cuprum’, an altered version of ‘cyprium’. The original name of copper is 
‘aescyprium’, refers to the island of Cyprus where the ancient copper mines 
were located.60 
Copper is a transition metal with atomic number 29 and an atomic 
weight of 63.55 Daltons. Copper participates in metabolism as a component of 
many metalloenzymes, including ceruloplasmin or ferroxidase I, cytochrome- c 
oxidase, copper/zinc superoxide dismutase, dopamine beta-hydroxylase, 
tyrosinase, monoamine oxidase, Diamine oxidase, lysyl oxidase (protein- 
lysine 6-oxidase) and ferroxidase II. 
 DIETARY SOURCES: 
The richest dietary sources of copper include nuts, seeds, legumes, and 
the bran and germ portions of grains, liver, kidneys, shellfish, oysters and 
crustaceans. Cow's milk has little copper.  
DAILY REQUIREMENTS OF COPPER:  
World Health Organisation estimated minimum daily requirements61 of 
copper is  
Male         :  0.6 mg/day 
Female     :  0.7 mg/day 
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ABSORPTION, TRANSPORT AND METABOLISM 
Copper is principally absorbed in small intestine as well as in the 
stomach and its absorption is reduced by zinc (via metallothionein), molybdate 
and iron and is increased by aminoacids and dietary sodium.62 
Absorbed copper is transported to liver in portal blood bound to 
albumin, where it is incorporated by hepatocytes into cuproenzymes and 
proteins and then exported to peripheral tissues. More than 90% copper 
exported from liver is in the form of glycoprotein - ceruloplasmin. A smaller 
amount of copper (10%) is transported in plasma bound to albumin and this 
copper is in equilibrium with plasma aminoacids. This fraction is essential for 
cellular uptake. 
About 0.5 to 2 mg of copper is excreted via bile into feces daily. Copper 
losses in urine and sweat are < 3% of dietary intake. Urine copper output is 
normally  < 60 µg/day.63 
FUNCTIONS OF COPPER:  
 Copper is essential for intracellular energy production, connective tissue 
formation, metabolism of iron (ceruloplasmin oxidizes ferrous to ferric ion and 
incorporates iron into transferrin and eventually into hemoglobin), synthesis of 
melanin, antioxidant function and regulation of gene expression.63 
COPPER DEFICIENCY: 
Copper levels in adults below 50µg/dL and for infants below 30µg/dL indicates 
copper deficiency.63  
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 INDIVIDUALS AT RISK FOR COPPER DEFICIENCY: 
Individuals at risk for copper deficiency are given below.63, 64, 65, 66, 67  
• Malnourished infants 
• Premature infants 
• Patients on total parenteral nutrition and prolonged enteral feeding via 
jejunostomy 
• Menke’s syndrome 
• Malabsorption syndrome-celiac disease, tropical sprue, cystic fibrosis 
cardiovascular disease 
COPPER TOXICITY: 
Toxicity arises from copper contamination of diet and water supplies. 
Acute poisoning occurs with accidental (or) intentional ingestion of copper 
sulphate. Wilson disease is a genetic disorder of copper metabolism that causes 
an increase in copper to toxic levels.68,69 
 
COPPER IN RENAL FAILURE:  
Plasma copper levels in chronic kidney disease patients are usually 
normal but could be lower than normal. In patients with proteinuria, urinary 
copper concentration increases, as it is lost along with bound proteins that lead 
to low plasma copper.59 
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LABORATORY ASSESSMENT OF COPPER: 
Plasma copper and ceruloplasmin assays are widely used to confirm 
copper deficiency. As 90% of copper is bound to ceruloplasmin, and factors 
that increase hepatic synthesis of ceruloplasmin, such as an acute phase 
reaction or the oral contraceptive pill, will increase plasma copper 
independently of dietary copper intake.70 
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 CERULOPLASMIN 
Ceruloplasmin (Molecular mass 132 KDa) is an alpha-2 globulin that 
contains approximately 95% of the total copper found in serum. Each molecule 
of ceruloplasmin contains 6 to 8 copper atoms. The high content of copper 
gives ceruloplasmin, a blue color. Ceruloplasmin also binds magnesium.  
Ceruloplasmin has single polypeptide chain with 1046 aminoacids and 
three glucosamine - linked oligosaccharide side chains, with a total 
carbohydrate content of 8% to 9.5%. Ceruloplasmin is synthesized in hepatic 
parenchymal cells, with a small amount synthesized in macrophages and 
lymphocytes. The normal plasma half-life of intact, holoceruloplasmin (copper 
replete) is 4 – 5 days, whereas that of apoceruloplasmin is few hours.71 The 
structure and functional sites of human ceruloplasmin is given in figure No.5. 
 
FUNCTIONS OF CERULOPLASMIN: 
The primary role of ceruloplasmin is that, it functions as an oxidant (or) 
anti-oxidant depending on factors such as presence of free ferric ions and 
ferritin binding sites. Ceruloplasmin is vitally important in the regulation of 
ionic state of iron (oxidizing ferrous to ferric ion and permitting its 
incorporation into transferrin without formation of toxic iron products). 
Ceruloplasmin transport small amounts of copper to tissues, which has 
separate membrane receptors for ceruloplasmin and albumin bound copper. 
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CLINICAL SIGNIFICANCE OF CERULOPLASMIN: 
¾ Increased plasma levels:    
• Primary cause        :    Genetic  
• Secondary cause :  Acute phase reactions, pregnancy and estrogen 
therapy 
¾ Decreased plasma levels: 
• Primary cause        : Genetic deficiency 
• Secondary cause    :  Dietary copper insufficiency (Malabsorption) 
•  Menke’s disease 
•  Wilson’s disease72 
 
LABORATORY ASSESSMENT:  
Ceruloplasmin is assayed immunochemically or functionally (copper 
oxidase activity). Immunochemical methods measure both the intact molecule 
and apoceruloplasmin and proteolytic fragments. Copper oxidase method 
measures only the native copper containing ceruloplasmin. 
Serum (or) plasma is preferred. After collection, the samples should be 
centrifuged as soon as possible to avoid spontaneous oxidation invitro.72 
 
 CERULOPLASMIN IN RENAL FAILURE: 
The urinary loss of ceruloplasmin is increased in proteinuria that results 
in decreased plasma levels of ceruloplasmin.59 
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 MATERIALS AND METHODS 
This is an age and sex matched comparative study. The present study is 
conducted after getting approval from the ethical committee of Stanley Medical 
College, Chennai. The study was conducted on 100 subjects that include two 
groups. Group 1 consists of 50 normal subjects and group 2 consists of 50 end 
stage renal disease patients on hemodialysis 2 times/week, between age group 
10 years and 74 years. Group 1 serves as control for group 2.  
For group 1, the subjects were volunteers from the patient’s relatives 
selected on the basis of good health as evidenced by medical history, complete 
physical examination and routine laboratory tests performed before the 
commencement of study.  
Group 2 patients were selected from those attending the Nephrology 
department of Stanley Medical College Hospital from April’ 07 to July’ 07. 
The study subjects were clearly informed of the nature of the study and the 
samples were collected after getting written informed consent. The samples 
were analyzed for iron, ferritin, total iron binding capacity (TIBC), transferrin 
saturation, transferrin, zinc, copper, ceruloplasmin and the results were 
analyzed based on the data collected. 
INCLUSION CRITERIA: 
• Patients with end stage renal disease undergoing hemodialysis 2 times 
per week 
• Age 10 years to 74 years 
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EXCLUSION CRITERIA: 
• Patients receiving parenteral iron supplements within 3 months of study 
and drugs such as aspirin, allopurinol, metformin, glucocorticoids and 
oral contraceptive pills. 
• Patients receiving recombinant human erythropoietin within 3 months of 
study. 
• History of recent blood transfusion. 
• History of bleeding episodes. 
• Patients with infection and inflammatory conditions like rheumatoid 
arthritis. 
• Patients with hepatocellular damage. 
• Patients with malignancies such as leukemia, lymphoma, breast 
carcinoma. 
• Patients not willing to give written informed consent were excluded 
from the study. 
 
SAMPLE COLLECTION: 
Venous blood 10 mL was collected just before dialysis from each 
subject. After collection, blood samples were centrifuged to separate serum. 
Biochemical analyses were carried out immediately after collection.  In 
case of delay, samples were stored at ─20°C. All the chemicals used were of 
analytical reagent grade. 
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DETERMINATION OF TRACE ELEMENTS IN SERUM: 
1.SERUM IRON: (µg/dL)  
Serum iron was estimated by the Ferrozine method73 of White J.M., and 
Flashka, H.A. 
PRINCIPLE: 
Serum is treated with buffer to prevent precipitation of proteins and to 
provide an acid medium to dissociate ferric-transferrin complex and to reduce 
ferric to ferrous ion. Addition of color reagent forms a deeply colored 
ferrozine-iron complex with maximum absorbance at 562nm. 
STANDARDISATION OF THE PROCEDURE: 
Preparation of standards: Ferrous sulphate (FeSO4.7H2O) was employed 
for preparation of iron standards. 
STOCK SOLUTION: 10 mg/dL of Iron 
            Dissolve 490 mg of FeSO4. 7H2O (British Drug House Ltd) in deionised 
water and add 1 mL of concentrated sulphuric acid and make upto 1litre with 
deionised water. 
WORKING STANDARDS: 
            Working standards of various concentrations were prepared from the 
stock solution as shown in Table No.10 (Refer Opposite Page). 
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REAGENTS: 
1. Ferrozine color reagent:   
400 mg of Ferrozine (Hi Media) and 2.5 g of Thiourea (Indian Drug and 
Pharmaceuticals) is dissolved in 100 mL of deionised water. Filtered and stored 
in a dark color bottle. The reagent is stable for two months. 
2. NaOH   12.5  mol/L:   
  50 g of NaOH (Indian Drug and Pharmaceuticals) is dissolved in 100 
mL of deionised water and stored in polyethylene bottle. 
3. Stock acetate buffer 1 mol/L:     
60mL of glacial acetic acid dissolved in 28 mL of 12.5 M NaOH and 
made up to 500 mL with deionised water. The pH of the buffer is adjusted with 
acetic acid (or) NaOH to 4.5. 
4. Iron reagent-A:  
6g of Sodium Lauryl Sulphate (Hi Media) dissolved in 10 mL of Stock 
acetate buffer and made up to 100 mL with deionised water. The solution is 
stable for 4 weeks. 
5. Iron reagent B: 
6 g of Ascorbic acid (Hi Media) and 1g of Sodium metabisulfite (Indian 
Drug and Pharmaceuticals) dissolved in 10 mL of stock acetate buffer and 
made upto 100 mL with deionised water. This solution is stored in dark brown 
bottle in the refrigerator and is stable for 2 weeks. 
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6. Iron Buffer Reagent: 
Equal volumes of Iron reagent A and B are mixed and prepared freshly. 
TABLE NO.11 
PROCEDURE 
  Test Standard Blank 
Sample 0.5 mL - - 
Standard - 0.5mL - 
Deionised water - - 0.5mL 
Iron buffer reagent 4.5mL 4.5mL 4.5mL 
 
Mix vigorously and incubate for 15 min at 37˚C in a water bath. Read 
the absorbance (A1) at 562 nm. 
0.1 mL of Ferrozine reagent is then added to all tubes and incubated for 
15 min in a water bath at 37˚C.Read the absorbance (A2) at 562 nm. 
ABSORBANCE OF IRON STANDARDS: 
Reagent blank = 0.187 
 
TABLE NO.12 
 
Concentration of 
Working Standard 
(µg/dL) 
Standard Absorbance Standard – Blank       Absorbance 
50 0.202 0.015 
100 0.215 0.028 
200 0.242 0.055 
300 0.272 0.085 
400 0.308 0.121 
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CALCULATION: 
A2-A1 (Unknown) 
Iron (µg/dL)  =   -----------------------   x   Concentration of Standard 
   A2-A1 (Standard) 
  
REFERENCE VALUES: 
Adults  
Male    : 60 - 150 µg/dL 
Female: 50 – 130 µg/dL74 
 
2. SERUM TOTAL IRON BINDING CAPACITY (µg/dL): 
 
TIBC was determined using Magnesium Carbonate absorption method75 
of Ramsay, 1957,1958. 
PRINCIPLE:   
An excess of iron is added in the form of ferric chloride to serum to 
saturate transferrin. The excess unbound iron is then precipitated with basic 
magnesium carbonate. After centrifugation, the iron in the supernatant is 
determined by Ferrozine method colorimetrically at 562 nm. 
REAGENTS: 
1. Ferric chloride Solution: 5µg iron per mL in 5 mmol/L HCl.                            
Stock solution containing 144 mg of anhydrous ferric chloride (Merck) in 
100 ml of 500mM HCl was prepared. The stock solution was diluted 1 in 
100 with deionised water to obtain a concentration of 5 µg of iron per mL in 
hydrochloric acid (5mmol).                     
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2. Light magnesium carbonate powder (Lobachem) 
 
PROCEDURE: 
1. One volume of serum is mixed with 3 volumes of ferric chloride solution 
and is covered. 
2. After 5 min, light magnesium carbonate powder (100 mg/mL of iron 
solution) was added and covered with parafilm .The solution was mixed 
continuously at 10 min intervals for upto 30 min. 
3. The solution was then centrifuged for 10 min and the supernatant was 
analyzed for iron using Ferrozine method. 
4. The result must be multiplied by factor 3 (Dilution factor for ferric chloride 
solution). 
 
REFERENCE INTERVAL FOR TIBC: 
Adults       :   270 – 380 µg/dL 
Reference interval for methods not requiring protein precipitation: 
Adults       :    280  - 400 µg/dL 74 
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3.  SERUM FERRITIN:(ng/mL) 
Serum ferritin was determined by micro plate immuno enzymometric 
sequential assay –ACCUBIND FERRITIN MICROPLATE ELISA KIT (LILLAC). 
PRINCIPLE: 
Monoclonal biotinylated antibody and serum containing ferritin antigen 
is added to micro plate wells coated with streptavidin to form an immobile 
complex. After that another antibody labeled with enzyme is added that 
interacts with the immobile complex to form an Antibody-Antigen-Biotinylated 
Antibody complex on the surface of well. When a substrate is added, it 
produces a color which is measured at 450nm using a microplate 
spectrophotometer. 
STANDARDS: 
Ferritin calibrators of 6 concentrations were provided with the kit. The 
given calibrators were 
0 ng/mL, 10 ng/mL, 50 ng/mL, 150 ng/mL, 400ng/mL, 800ng/mL. 
CALIBRATION: 
The absorbance of the calibrators (Table No.13) is plotted against the 
concentration of ferritin on a graph paper as shown in graph no.2. The 
concentration of ferritin for an unknown is determined by plotting the 
absorbance of unknown on the vertical axis of the graph and reading the 
concentration (ng/mL) from the horizontal axis of the graph. 
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REAGENTS: 
1. Biotinylated monoclonal mouse IgG in buffer, dye and preservative. Store 
at 2˚ – 8˚ C 
2. Horseradish peroxidase labeled anti – ferritin IgG antibody in buffer, 
dye and preservatives. Store at 2˚ – 8˚ C 
3. Streptavidin coated micro plate – 96 wells. Store at 2˚ – 8˚ C 
4. Wash Solution Concentrate containing a surfactant in buffered saline.                                       
The wash concentrate was diluted in 1 litre of deionised water for use. Store 
at 2˚ – 30˚ C 
5. Substrate A containing Tetra methyl benzidine (TMB) in buffer. Store at 
2˚ – 8˚ C 
6. Substrate B Containing hydrogen peroxide in buffer. Store at 2˚ – 8˚ C 
7. Substrate A and Substrate B were mixed in equal proportions for use. Store 
at 2˚ – 8˚ C 
8. Stop solution containing strong acid (1N HCl). Store at 2˚ – 30˚ C 
 
PROCEDURE: 
1. 25µL of calibrators were pipetted into first 6 wells and the samples into the 
remaining wells. 
2. 0.1 mL of Biotinylated antibody was then added to each well. 
3. After swirling the plate for 20 – 30 sec, the plate was incubated for 30 
minutes. 
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4. Then the plate was washed 3 times with 300µL of wash buffer and 
decanted. 
5. 0.1 mL of anti – ferritin enzyme labeled antibody was then added. 
6. The plate was incubated for 30 min after gentle swirling. 
7. The plate was again washed 3 times with 300 µL of wash buffer and 
decanted. 
8. 0.1 mL of substrate was added and incubated for 15 min. Then 0.05 mL of 
stop solution was added and the plate was mixed and the absorbance was 
read at 450 nm. (Using a reference wavelength of 620 – 630 nm) 
VALIDITY OF THE ASSAY: 
Maximum Absorbance (800 ng/mL calibrator) ≥ 1.2 
Maximum Absorbance (0 ng/mL calibrator) ≤ 0.1 
TABLE NO.13 
                     ABSORBANCE OF FERRITIN CALIBRATORS 
Concentration of Standard 
(ng/mL) Absorbance of Ferritin 
0 0.01 
10 0.11 
50 0.58 
150 1.14 
400 1.51 
800 1.86 
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REFERENCE RANGE: 
Adult male      : 20 – 250 ng/mL 
Adult Female  : 10 – 120 ng/mL 76 
ABSOLUTE IRON DEFICIENCY IN HEMODIALYSIS PATIENTS:  
Serum Ferritin < 100 ng/mL 42 
 
4. SERUM TRANSFERRIN: (g/L) 
Calculated from Total iron binding capacity.36 
Serum Transferrin (g/L) = 0.007 x TIBC  (µg/dL) 
Derivation of factor: 
     Theoretical ratio of TIBC (µmol/L) to transferrin (g/L) is 25.177,78 
∴  TIBC (µmol/L) = 25.1 x Transferrin  (g/L) 
     1 mol of Iron = 55.8 g/L 
     1µmol = 55.8 µg/L 
∴  1 µg/L = 1/ 55.8  
      1 µg/L  =  0.0179 µmol 
      TIBC (µg/L)  = 25.1/0.0179 x Transferrin (g/L) 
 ∴  Transferrin (g/L) = 0.007 x TIBC (µg/dL) 
 
  The reference interval for serum transferrin is given in Table No.14 (Refer 
Opposite Page). 
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5. TRANSFERRIN SATURATION: (%) 
Serum transferrin saturation 37is determined as follows, 
Serum Iron 
Transferrin Saturation    = -------------- x   100 
      TIBC 
  
REFERENCE RANGE : 
 Male   : 20 – 55 % 
Female: 15 –50 % 80 
ABSOLUTE IRON DEFICIENCY IN HEMODIALYSIS PATIENTS:  
 Serum Transferrin Saturation <20 % 42 
 
 
6. SERUM ZINC: (µg/dL) 
Zinc was measured Colorimetrically with 5-Brom-PAPS [GREINER 
COMMERCIAL KIT]. 
PRINCIPLE: 
Zinc forms red chelate complex with 2-(5-Bromo-2-Pyridylazo)-5-(N-
Propyl-N-Sulfopropylamino)-Phenol. The increase in absorbance is measured 
at 560nm and is proportional to concentration of total zinc in the sample. 
STANDARD PREPARATION: 
The standard provided with the kit was 200 µg/dL of Zinc. 
Working standards were prepared from the given concentration as shown in 
Table No.15 (Refer Opposite Page). 
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REAGENTS: 
1. Monoreagent(ready to use) 
 
  The reagent is stable when it is stored at 2˚ – 25˚ C 
                                         
PROCEDURE: 
Wavelength: 560 nm 
Light Path: 1cm 
Temperature: 25˚C/37˚C 
TABLE NO.16 
 
Mix and incubate for 10 min at 25˚ C (or) 5 min at 37˚ C. Read the 
absorbance at 560 nm. 
1. 5-Brom-PAPS = 0.02 mmol 
2. Bicarbonate buffer pH 9.8 = 200 mmol 
3. Sodium Citrate = 170 mmol 
4. Dimethyl glyoxime = 4 mmol 
5. Detergent = 1% 
 Standard Test Reagent blank 
Reagent 1000µL 1000µL 1000µL 
Sample - 50µL - 
Standard 50µL - - 
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TABLE NO.17 
                                ABSORBANCE OF ZINC STANDARDS 
 
REAGENT BLANK = 0.105 
 
CALCULATION: 
    Test absorbance  
Zinc (µg/dL)      =    -------------------------    x   Concentration of Standard  
Standard absorbance  
 
REFERENCE RANGE: 
Serum Zinc :  70 – 150  µg/dL81  
 
 
7. SERUM COPPER: (µg/dL) 
Serum Copper was measured using Diethyldithiocarbamate method 82 of 
Eden and Green, 1940; Ventura.S and King E. J.1951. 
PRINCIPLE: 
After releasing copper from protein by hydrochloric acid, the proteins 
were precipitated by trichloroacetic acid, and the copper extracted into mixture 
Concentration Of Zinc 
(µg /dL) Standard Absorbance 
Standard – Blank 
Absorbance 
50 0.166 0.061 
100 0.227 0.122 
200 0.345 0.240 
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of amyl alcohol and ether as a golden yellow colored complex with sodium 
diethyldithiocarbamate for colorimetric determination at 440nm. 
                                                
STANDARDISATION: 
Copper sulphate (CuSO4.5H2O) was used to prepare the standard 
solutions. 
STOCK SOLUTION: 10 mg/dL. 
To 393 mg of CuSO4.5H2O (chemspure co.), 1 mL of Concentrated 
Sulphuric acid was added and made to 1 litre with deionised water. 
Working standards were prepared from 10 mg% of stock solution as 
shown in Table No.18 (Refer Opposite Page). 
REAGENTS: 
1. Hydrochloric acid, 100 mmol/L 
2. Hydrochloric acid, 6 mol/L 
3. Trichloroacetic acid (TCA) solutions, 200 g/L and 50 g/L (Qualigens) 
4. Sodium pyrophosphate solution, 200 g/L (S.D.Fine Chemicals) 
5. Ammonia, Sp.gr. 0.88 (Merck) 
6. Sodium diethyldithiocarbamate solution, 4 g/L (British Drug House Ltd) 
7. Amyl alcohol (Ranbaxy Laboratories) - Ether (Hi Media) mixture 
containing equal volumes each. 
8. Powdered anhydrous Sodium Sulphate. (Hi Media) 
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PROCEDURE: 
1. To 3ml of serum, 1mL of 100mmol/L HCl was added and warmed until the 
solution turns cloud. 
2. Cool and 1.5 mL of 6 mmol/L HCl was added and allowed to stand for  
10 min. 
3. 3 mL of 200g/L TCA was added and allowed to stand for few minutes and 
centrifuged to separate the supernatant.  
4. 3 mL of 50 g/L TCA was then added to wash the precipitate and the 
supernatant fluids were combined. 
5. 1 mL of sodium pyrophosphate, 2 mL of ammonia, and 1 mL of sodium 
diethyldithiocarbamate was then added. 
6. Shake the solution with 5 mL amyl alcohol and ether mixture for 2 min to 
extract copper. 
7. The organic layer was removed and dried with anhydrous sodium sulphate. 
8. The absorbance was read using violet filter (440 nm). 
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TABLE NO.19 
                            ABSORBANCE OF COPPER   STANDARDS 
REAGENT BLANK= 0.028                               
 
 
 CALCULATION: 
Test absorbance – Blank absorbance 
Copper (µg/dL)  = 
Standard absorbance – Blank absorbance 
x Concentration of Standard  
 
REFERENCE INTERVAL:  
Birth to 6 months : 20 –70 µg/dL 
6 months - 6 years : 90 – 190 µg/dL 
6 years – 12 years : 80 - 160 µg/dL 
Adult Male  : 70 – 140  µg /dL 
 
Adult Female : 80 – 155 µg /dL 83 
 
Concentration of 
Standard (µg/dL) Standard absorbance 
Standard - Blank 
Absorbance 
50 0.070 0.042 
100 0.113 0.085 
200 0.194 0.166 
300 0.270 0.242 
400 0.381 0.353 
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8. CERULOPLASMIN:  (UNITS) 
Ceruloplasmin was determined by Copper Oxidase activity using     
Para-phenylenediamine by two-point procedure of Henry84 in 
spectrophotometer. 
PRINCIPLE: 
Ceruloplasmin catalyses the oxidation of Paraphenylenediamine 
hydrochloride to give dark lavender color product which is measured at 530nm. 
REAGENTS: 
1.  Acetate Buffer. PH 6.0    (0.1 M) 
     10 mL of 0.1 M acetic acid (0.57 mL of glacial acetic acid made upto       
100 mL) was added to 200 mL of 0.1 M Sodium acetate (0.82 g 0f 
anhydrous sodium acetate in 100 mL of water). Adjust the pH using 0.1M 
acetic acid (or) sodium acetate. 
2.  Sodium Azide :  0.1% 
0.1 g of Sodium azide (S.D Fine chemicals)  in 100 mL of 0.1 M acetate 
buffer. 
3.  Paraphenylene Diamine : 0.25 % 
0.25 g of paraphenylene Diamine (Hi Media) in 100 mL of 0.1 M acetate 
buffer 
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TABLE NO.20 
 
   PROCEDURE  
 
Reagents Blank Test 
Acetate Butter 1ml 2ml 
0.25% Paraphenylene 
Diamine in Acetate 
buffer 
1ml 1ml 
Sodium Azide 1ml - 
 
 
Bring the test solutions to 37°C by placing in water bath. 
 
Serum 0.1ml 0.1ml 
 
 
After 10 and 40 min of incubation at 37°C, read the absorbance at 10 min and  
 
40 min interval at 540nm. 
 
CALCULATION: 
 Ceruloplasmin (Units)     =  
 
REFERENCE INTERVAL: 
Normal Range = 250 – 570 Units 84 
 
 
(T – B) − (T – B) X
(40 MIN)  (10 MIN)  
1000 
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9. BLOOD UREA: (mg/dL) 
Blood Urea was determined by enzymatic method using BUN – 
Glutamate Dehydrogenase method85 in Micro 200 Semi autoanalyser at 340nm. 
PRINCIPLE: 
          Urea in the presence of urease forms ammonia, which reacts with          
2-oxoglutarate and NAD(P)H in the presence of glutamate dehydrogenase to 
form NAD(P) and glutamate. The decrease in the absorbance of NAD(P)H is 
measured at  340nm. 
REFERENCE INTERVAL:   
New Born : 8  – 26 mg/dL 
Infants and Children : 11 – 38mg/dL 
Adults                            : 15 – 39 mg/dL 
Age >60 years               :  17 – 45 mg/dL 86 
 
10. SERUM CREATININE: (mg/dL) 
Serum creatinine was determined by Jaffe’s alkaline picrate method 87 in 
Micro 200 semi auto analyzer at 505nm. 
 
PRINCIPLE: 
Creatinine reacts with alkaline picrate and forms a red-orange adduct which is 
measured at 505 nm. 
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REFERENCE INTERVAL: 
New Born : 0.3 – 1.0 mg/dL 
Infant  : 0.2 – 0.4 mg/dL 
Children  : 0. 3 –0.7 mg/dL 
Adolescent : 0.5 – 1.0 mg/dL 
Adult male : 0.7 – 1.3 mg/dL 
Adult Female : 0.6 – 1.1 mg/dL 88 
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 RESULTS AND STATISTICAL ANALYSIS 
 
 
 The total number of subjects included for the study was 100. Out of 100, 
50 were cases (Patients with Chronic kidney disease on hemodialysis) and 50 
controls. 
The distribution of age among the control group and the study group 
were as shown in Table No.21 
The patients and the controls were grouped in to four according to the 
age as shown in Table No.22 
The distribution of sex among the control group and the study group  
were as shown in Table No.23 
Mean and standard deviation were estimated for each group.i.e cases 
and controls. Data were expressed as mean ± standard deviation. 
 Mean values were compared using student independent ‘t’ test. 
Student independent ‘t’ test was employed to find out the ‘p’ value. 
Age group wise comparisons of mean level of trace elements in study 
and control group were given in Table No. 25 to Table No.28. 
Sex wise comparison of mean level of trace elements in study and 
control group was given in Table No.29 and Table No.30. 
Pearson’s correlation analysis was done to assure the relationship of Iron 
with Copper and Zinc in the study group and was given in Table No. 31. The 
results of the present study were given in Table No.24. 
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TABLE NO.21 
AGE DISTRIBUTION AMONG THE STUDY AND 
CONTROL GROUP 
 
 
Group N Mean Age (Years) 
Standard 
Deviation Student t-test 
Study 50 41.36 15.053 
Control 50 40.68 13.969 
P=0.82 
Not significant 
 
                 
TABLE NO.22 
GROUPING OF STUDY AND CONTROL MATERIALS  
BASED ON AGE 
 
Group 
Age in Years 
Study Controls 
Total Chi square Test 
<25 9 9 18 
25-40 16 16 32 
40-60 17 20 37 
>60 8 5 13 
Total 50 50 100 
χ2=0.93     
P=0.81    
Not significant 
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TABLE NO.23 
DISTRIBUTION OF SEX AMONG THE STUDY GROUP AND 
CONTROL GROUP  
 
Group 
Sex 
Study Control 
Total Chi square Test 
Male 33 33 66 
Female 17 17 34 
Total 50 50 100 
χ2=0.00         
 
P=1.00    
 
Not significant 
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TABLE NO.24 
 
MEAN, STANDARD DEVIATION AND TEST OF SIGNIFICANCE  
OF MEAN VALUES BETWEEN STUDY GROUP AND  
CONTROL GROUP 
 
Study Group Control Group 
Variable 
Mean ± S.D Mean ± S.D 
P Value 
Blood Urea  
(mg/dL) 142.56 ± 28.871 23.92 ± 5.795 
<0.001 
Significant 
Serum 
Creatinine 
(mg/dL) 
7.97±3.184 0.98± 0.195 <0.001 Significant 
Serum Iron 
(µg/dL) 90.59±32.821 103.38 ± 20.565 
<0.02 
Significant 
Serum TIBC 
(µg/dL) 629.22±147.250 319.91± 50.081 
<0.001 
Significant 
Serum Ferritin 
(ng/mL) 73.82±36.012 103.24± 39.997 
<0.001 
Significant 
Serum 
Transferrin 
Saturation (%) 
14.94±6.141 32.31± 4.047 <0.001 Significant 
Serum 
Transferrin 
(mg/dL) 
439.92±102.906 224.19± 35.575 <0.001 Significant 
Serum copper 
(µg/dL) 77.65±37.438 103.22 ± 27.226 
<0.001 
Significant 
Serum 
ceruloplasmin 
(Units) 
234.46±80.952 332.14± 52.915 <0.001 Significant 
Serum zinc 
(µg/dL) 57.42±17.869 101.48 ±18.076 
<0.001 
Significant 
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TABLE NO.25 
AGE GROUPWISE COMPARISON OF MEAN LEVELS OF TRACE 
ELEMENTS IN STUDY SUBJECTS AND CONTROLS. 
 
AGE < 25 YEARS 
Cases Controls Variable Mean ± SD Mean ± SD P Value 
Blood Urea 
(mg/dL) 122.22±33.607 24.44±5.411 
< 0.001 
significant 
Serum Creatinine 
(mg/dL) 6.57±2.515 0.96±0.142 
< 0.001 
significant 
Serum Iron 
(µg/dL) 74.48±28.441 96.29±22.049 
< 0.08 Not 
significant 
Serum TIBC 
(µg/dL) 587.51±121.546 304.41±38.799 
<0.001 
significant 
Serum Ferritin 
(ng/mL) 62.31± 21.298 107.89±53.629 
<0.06 
Not significant 
Serum 
Transferrin 
Saturation (%) 
12.77±4.195 31.59±5.579 < 0.001 significant 
Serum 
Transferrin 
(mg/dL) 
410.78±84.878 213.07±27.158 < 0.001 significant 
Serum copper 
(µg/dL) 93.99±47.317 104.62±22.858 
< 0.55 
Not significant 
Serum 
ceruloplasmin 
(Units) 
260.00±112.299 365.56±65.740 < 0.05 significant 
Serum zinc 
(µg/dL) 55.00±12.826 106.44±17.067 
< 0.001 
significant 
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TABLE NO.26 
 
 AGE 25 – 40 YEARS 
Cases Controls 
Variable 
Mean±SD Mean ±  SD 
P Value 
Blood Urea 
(mg/dL) 149.13±26.374 22.06±5.916 
< 0.001 
significant 
Serum 
Creatinine 
(mg/dL) 
8.22±3.204 0.94±0.190 < 0.001 significant 
Serum Iron 
(µg/dL) 110.90±39.344 108.57±21.376 
< 0.83 
Not Significant 
Serum TIBC 
(µg/dL) 624.05±197.356 323.32±47.083 
< 0.001 
significant 
Serum 
Ferritin 
(ng/mL) 
85.33±42.072 96.24±28.646 < 0.06 Not significant 
Serum 
Transferrin 
Saturation 
(%) 
19.05±8.062 33.50±4.215 < 0.001 significant 
Serum 
Transferrin 
(mg/dL) 
436.38±138.124 226.31±32.965 < 0.001 significant 
Serum copper 
(µg/dL) 80.03±39.670 110.75±30.014 
<0.01 
significant 
Serum 
ceruloplasmin 
(Units) 
225.81±89.066 334.25±41.760 < 0.001 significant 
Serum zinc 
(µg/dL) 56.88±19.609 102.31±17.484 
< 0.001 
significant 
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TABLE NO.27 
AGE    41 – 60 YEARS 
 
 
                                         
Cases Controls 
Variable 
Mean±SD Mean ± SD 
P Value 
Blood Urea 
(mg/dL) 148.76±26.459 24.85±6.293 
< 0.001 
significant 
Serum 
Creatinine 
(mg/dL) 
9.01±3.635 1.00±0.218 <0.001 significant 
Serum Iron 
(µg/dL) 82.86±26.626 103.23 ± 20.507 
< 0.01 
significant 
Serum TIBC 
(µg/dL) 618.67 ± 107.593 321.47 ± 57.491 
< 0.001 
significant 
Serum 
Ferritin 
(ng/mL) 
70.39  ±40.199 105.48 ± 46.798 
<0.05 
significant 
 
Serum 
Transferrin 
Saturation 
(%) 
13.57 ± 4.273 32.16 ±3.451 < 0.001 significant 
Serum 
Transferrin 
(mg/dL) 
432.71 ± 75.332 223.97± 41.359 < 0.001 significant 
Serum copper 
(µg/dL) 64.35 ± 25.075 96.39 ± 28.039 
<0.001 
significant 
Serum 
ceruloplasmin 
(Units) 
222.35 ± 47.202 317.25 ±55.781 <0.001 significant 
Serum zinc 
(µg/dL) 59.59 ± 17.418 96.00 ± 17.290 
<0.001 
significant 
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TABLE NO.28 
AGE > 60 YEARS 
 
 
 
Cases Controls 
Variable 
Mean±SD Mean ± SD 
P Value 
Blood Urea 
(mg/dL) 139.13 ± 26.755 25.20 ± 3.564 
< 0.001 
significant 
Serum 
Creatinine 
(mg/dL) 
6.83 ± 2.172 1.04±0 .230 < 0.001 significant 
Serum Iron 
(µg/dL) 84.53 ± 14.654 100.12  ± 16.210 
<0.10 
Not significant
Serum TIBC 
(µg/dL) 708.88 ± 123.092 330.60  ± 54.395 
< 0.001 
significant 
Serum 
Ferritin 
(ng/mL) 
72.66  ± 29.238 112.92  ± 32.358 
< 0.05 
significant 
 
Serum 
Transferrin 
Saturation 
(%) 
12.03  ± 1.981 30.33±1.827 < 0.001 significant 
Serum 
Transferrin 
(mg/dL) 
495.13  ± 85.503 241.86 ± 34.707 < 0.001 significant 
Serum copper 
(µg/dL) 83.50 ± 40.740 103.88  ± 21.406 
< 0.34  
Not significant
Serum 
ceruloplasmin 
(Units) 
248.75  ± 88.144 324.80±25.114 < 0.09  Not significant
Serum zinc 
(µg/dL) 56.63  ± 22.570 111.80  ± 22.632 
<0.001 
significant 
62
 
TABLE NO.29 
 
SEX WISE COMPARISON OF MEAN LEVELS OF TRACE 
ELEMENTS IN STUDY SUBJECTS AND CONTROLS. 
                                                     MALE 
 
 
Cases Controls 
Variable 
Mean±SD Mean ± SD 
P Value 
Blood Urea 
(mg/dL) 143.76  ± 28.099 24.42  ± 5.668  
< 0.001 
significant 
Serum 
Creatinine 
(mg/dL) 
8.08  ± 3.380 0.98 ± 0.192 <0.001 significant 
Serum Iron 
(µg/dL) 93.72  ± 31.598 102.41   ± 19.469  
<0.18 
Not significant 
Serum TIBC 
(µg/dL) 625.79  ± 129.126  321.11 ±48.652  
<0.001 
significant 
Serum 
Ferritin 
(ng/mL) 
   72.60 ± 33.042  109.58   ± 37.856  
<0.001 
significant 
 
Serum 
Transferrin 
Saturation 
(%) 
15.67   ± 6.602  31.93 ± 4.179  <0.001 significant 
Serum 
Transferrin 
(mg/dL) 
437.45    ± 90.106  225.20  ± 34.835  <0.001 significant 
Serum copper 
(µg/dL) 80.96   ± 38.126 100.82   ± 24.889  
<0.01 
significant 
Serum 
ceruloplasmin 
(Units) 
239.15 ± 74.534 341.79 ± 49.939 <0.01 significant 
Serum zinc 
(µg/dL)  57.94  ± 18.048  100.97   ± 17.758 
<0.001 
significant 
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TABLE NO.30 
FEMALE 
 
                                   
 
 
 
                                           
Cases Controls 
Variable 
Mean±SD Mean ± SD 
P Value 
Blood Urea 
(mg/dL) 140.24  ± 31.061 22.94   ±6.088 
<0.001 
significant 
Serum Creatinine 
(mg/dL) 7.75  ± 2.850 0.96   ± 0.206 
<0.001 
significant 
Serum Iron 
(µg/dL) 84.51    ±35.251 105.25    ± 23.053 
<0.05 
significant 
Serum TIBC 
(µg/dL) 635.86  ±181.617 317.57  ±54.206 
<0.001 
significant 
Serum Ferritin 
(ng/mL) 75.73± 41.295 93.74    ± 42.444 
<0.23  
Not significant 
Serum 
Transferrin 
Saturation 
(%) 
13.51 ± 5.002 33.04  ±3.789 <0.001 significant 
Serum 
Transferrin 
(mg/dL) 
444.71   ± 127.106 222.30   ± 37.945 < 0.001 significant 
Serum copper 
(µg/dL) 70.81    ± 36.196 107.88    ± 31.562 
 
< 0.01 
significant 
Serum 
ceruloplasmin 
(Units) 
225.35  ± 93.940 313.41  ± 54.978 <0.01 significant 
Serum zinc 
(µg/dL) 56.41   ± 18.021 102.47   ±19.193 
<0.001 
significant 
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TABLE NO.31 
 
CORRELATION OF SERUM IRON WITH COPPER AND ZINC IN 
CHRONIC KIDNEY DISEASE PATIENTS UNDERGOING 
HEMODIALYSIS 
 
Variables 
Pearson’s 
Correlation 
Coefficient 
(r) 
Significance 
(p) Interpretation 
Iron Vs Copper 0.294 0.04 
Significant and 
Positive 
  Correlation   
Iron Vs Zinc 0.18 0.28 Not significant and Positive correlation 
  
Correlation always lies between –1 to +1 
It is represented by ‘r’. 
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 DISCUSSION 
 
Recent studies have focused on the possible role of trace element 
depletion in the pathogenesis of uremic symptoms such as anemia, dysguesia 
and impotence. It is well known that patients on long-term hemodialysis are at 
risk of developing changes in the trace element metabolism89, which can 
further induce different abnormalities in these patients. Such abnormalities of 
trace element metabolism and their concentrations have been reported. 
Lawson DH et al90 has reported iron deficiency in patients with chronic 
kidney disease on regular hemodialysis treatment. In the present study, 
comparison of metabolic indicators of iron in patients with chronic kidney 
disease on hemodialysis with control group (Table No.24) reveals significant 
changes in the iron metabolism. This is evidenced by statistically significant 
decrease in serum iron, transferrin saturation and ferritin, and increase in serum 
transferrin and total iron binding capacity levels in the study group. 
Comparison of indicators of iron metabolism between age matched 
study and control group and in both sexes (Table No.25 to Table No.30) did not 
show a uniform significance. This is probably because of the small number of 
patients taken for the study. 
        Iron deficiency is common in chronic kidney disease particularly in 
hemodialysis patients for several reasons:91,92 
1. Substantial loss of blood from frequent blood tests and retention of 
blood in the dialysis tubing and the dialyser. 
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2.  Blood loss in the gastrointestinal tract that cannot be compensated for 
by sufficient absorption from the diet. 
3. Recombinant human erythropoietin administered to correct anemia in 
patients on hemodialysis induces a rise in hemoglobin concentration and 
depletes the body iron stores. 
In the present study, comparison of the levels of serum copper, 
ceruloplasmin and zinc in study group with control group (Table No.24) reveal 
abnormalities in copper and zinc levels in patients on hemodialysis. It has been 
found that serum copper levels are significantly lower than control subjects, but 
are within normal reference range83. The levels of serum ceruloplasmin and 
zinc are significantly lower than the reference range81, 84 in the study group 
suggesting their deficiency states. In this study, it has been found that, there is 
no significant influence of age and sex on copper and zinc levels (Table No.25 
to Table No.30). 
Yilmaz M. Emin et al93 have reported significantly low plasma zinc and 
copper levels in patients on hemodialysis compared to normal subjects. Nancy 
J Emenaker et al94 have reported low plasma copper and ceruloplasmin 
activities in patients undergoing hemodialysis with membranes that are not 
copper based. Another study by Van Renterghem D et al95 have reported low 
serum zinc levels in patients on hemodialysis. This low level of zinc is 
explained by the removal of this element when the dialysate used contains 
sufficiently low concentration of zinc. 
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The deficiency of copper, ceruloplasmin and zinc in chronic kidney 
disease has been attributed to excessive loss in urine due to proteinuria. When 
patients on dialysis are given oral iron therapy (as ferrous sulphate), zinc 
absorption is reduced due to competition of divalent trace elements for the 
divalent metal transporter (DMT-1). This reduced absorption of zinc and the 
loss of zinc in dialysis fluid results in zinc depletion and deficiency in patients 
on frequent dialysis. As zinc is a cofactor for δ – amino levulinate 
dehydratase96 in heme synthesis, zinc deficiency can interfere with hemoglobin 
synthesis and results in anemia. Zinc depletion in patients on hemodialysis 
leads to anorexia, dysguesia, hyposmia, dysosmia, impotence and impaired 
immunity. Zinc deficiency also correlates with signs of malnutrition in patients 
on hemodialysis97. 
 Low serum copper and ceruloplasmin levels cause deficient ferroxidase 
activity and interfere with iron transport. This results in iron deficiency 
symptoms like anemia. The Karl Pearson Correlation Coefficient between 
serum iron and copper (Table No.31) is calculated and compared in the study 
group. A significant positive correlation between these two parameters is 
observed. Similarly, comparison of the Karl Pearson correlation coefficient 
between serum iron and zinc (Table No.31) shows a non-significant and 
positive correlation between these parameters. This shows the linear 
relationship between serum iron, copper and zinc in the study group. 
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Trace element supplementation to the patients with chronic kidney 
disease on long-term hemodialysis is necessary to avert the complications of 
trace element depletion. Patients on maintanence hemodialysis become iron 
depleted and require iron therapy. In a study on patients with hemodialysis 
associated anemia, untreated patients suffer a net iron deficit of approximately 
1 mg/day.98 The exact amount of iron needed and best route of administration 
are still uncertain. Carter et al99 has suggested that oral iron therapy is 
inconsistent in its effects and parenteral iron should be given to patients. 
Another study by Eschbach et al100 has found that absorption of inorganic iron 
is normal in chronic kidney disease and Brozovich et al101 has suggested that 
oral iron is as effective as parenteral iron. 
Zinc and copper deficiency occur together in patients on frequent 
dialysis and aggravate the iron deficiency anemia. Probably, providing 
supplements of zinc and copper can augment treatment of the anemia 
associated with frequent dialysis. Supplementation of iron, copper and zinc to 
the patients on hemodialysis should be adequately spaced to avoid interference 
in their absorption from gastrointestinal tract. Trace mineral supplementation 
will probably improve the quality of life in patients with kidney failure on 
hemodialysis. 
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 CONCLUSION 
The present study shows that there is a disturbance in the metabolism of 
trace elements such as iron, copper and zinc in patients with chronic kidney 
disease on long-term hemodialysis. Trace element supplementation is 
necessary to improve the morbidity and clinical status in patients undergoing 
hemodialysis. 
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SCOPE FOR FURTHER STUDY 
 
 
 
¾ Further studies are needed to elucidate the clinical impact of other trace 
elements such as Aluminium, Magnesium, Molybdenum, Cadmium, 
Lead, Selenium and Cobalt on patients undergoing long-term 
hemodialysis. 
 
¾ Newer methods of measuring iron status in patients on hemodialysis 
such as reticulocyte hemoglobin content and serum transferrin receptor 
and percent hypochromic red blood cells can be used that are more 
sensitive and specific than current iron parameters. 
 
¾ Trace element concentration in the dialysate fluid can be estimated to 
evaluate the possible consequences of contamination with the trace 
elements e.g. Aluminium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE NO.1 
 
STAGES OF CHRONIC KIDNEY DISEASE13 
 
Stage Description GFR mL/min/1.73m2 
 
At Increased risk 
90 
 (With Chronic Renal 
Disease risk factors) 
1 Kidney damage with normal 
or increased GFR 
90 
2 Kidney damage with mildly 
decreased GFR 
60-89 
3 Moderately decreased GFR 30-59 
4 Severely decreased GFR 15-29 
5 Renal Failure <15 (or dialysis) 
 
TABLE NO. 2 
 
FOODS RICH IN HEME AND NON-HEME IRON 
    
Heme iron Non heme iron 
 
Liver 
Meat 
Poultry 
Fish 
 
Green leafy vegetables 
Cereals 
Nuts 
Legumes 
Oilseeds 
Jaggery 
Dried fruits 
 
 
 
 
 
TABLE NO.2 (a) 
 
RECOMMENDED DAILY INTAKE OF IRON 28(a) 
 
 
Category Age Recommended 
daily intake (mg) 
Infants (Full term) 0 – 3 months 
3- 6 months 
6- 12 months 
- 
6.6 
8.8 
Children  
(Male and Female) 1 – 10 years 10 
 Male 10 – 18 years 
>18 years 
12 
10 
Females 
    Non-Pregnant 
    Pregnant 
    Postmenopausal 
 
 
10- 45 years 
15 
45 
10 
TABLE NO.3 
 
COMPARTMENTS OF IRON AND ITS COMPOSITION: 
(Average 70 kg man) 32 
 
 
Compartment Iron Content 
(mg) 
Total Body Iron 
(%) 
Hemoglobin 2000 67 
Storage Iron  
(Ferritin, Hemosiderin) 
1000 27 
Myoglobin 130 3.5 
Labile Pool 80 2.2 
Transport Iron 3 0.08 
Other Tissue Iron 8 0.2 
 
TABLE NO. 4 
 
CLINICAL SIGNIFICANCE OF SERUM IRON 
 
Decreased Increased 
Physiological Physiological 
Diurnal- Evening 
Menstruation 
Morning 
Oral Contraceptives 
Pathological Pathological 
Iron deficiency 
Chronic Disease- Renal Failure 
Malignancy 
Inflammation  
Recent Blood Loss 
Ineffective Erythropoiesis 
Megaloblastic anemia 
Thalassemia major 
Sideroblastic anemia 
Hemolytic anemia 
Aplastic anemia 
Viral hepatitis 
Hemochromatosis 
Acute iron poisoning 
 
 
TABLE NO.5  
 
CLINICAL SIGNIFICANCE OF SERUM  
TRANSFERRIN AND TIBC 
 
Decreased Increased 
Physiological Physiological 
 Pregnancy 
Oral Contraceptives 
Pathological Pathological 
Inflammation 
Infection 
Malignancy 
Liver disease 
Nephrotic syndrome 
Malnutrition 
Megaloblastic and 
Hemolytic anemia 
Hemochromatosis 
 
Iron Deficiency 
Hepatitis 
 
TABLE NO.6 
 
CLINICAL SIGNIFICANCE OF SERUM TRANSFERRIN 
SATURATION 
 
Decreased Increased 
Physiological Physiological 
Diurnal- Evening 
Pregnancy 
Morning 
Pathological Pathological 
Chronic Disease 
Hemochromatosis 
Thalassemia Major 
Sideroblastic anemia 
Acute iron poisoning 
 
 
 
TABLE NO.7 
 
CHANGES IN SERUM FERRITIN 
 
Decreased Increased 
Iron deficiency anemia 
Hypothyroidism 
Ascorbate deficiency 
Fever 
Acute infection 
Rheumatoid arthritis 
Chronic inflammatory disease 
Liver damage (acute or chronic) 
Iron overload (Hemochromatosis) 
 
 
 
 
 
TABLE NO.8 
 
RECOMMENED DAILY ALLOWANCE FOR ZINC43 
 
 Age(Years) Males 
(mg/dL) 
Females 
(mg/dL) 
Infants 0 - 0.5 
0.5 – 1 
5 
5 
5 
5 
Children 1 – 3 
4 – 6 
7 – 10 
10 
10 
10 
10 
10 
10 
Adolescents 11 – 14 
15 – 18 
15 
15 
12 
12 
Adults 19 – 24 
25- 50 
> 50 
15 
15 
15 
12 
12 
12 
Pregnancy   15 
Lactation 0 – 6 Months 
7 – 12 Months 
 19 
16 
 
 
TABLE NO. 9 
 
PLASMA ZINC LEVELS IN NORMAL SUBJECTS AND 
  
PATIENTS WITH RENAL FAILURE59 
 
Group Plasma Zinc Levels( µg/dL) 
81+ 13 
84 + 11 
108 + 20 
96 +13 
85 +18 
Normal Subjects  
50 + 9 
63 +5 
71 + 7 
261 + 92 
80 + 16 
Hemodialysis patients  
102 + 32 
117 + 15 
65 + 13 Uremic patients not treated with dialysis 
81 +11 
  
 
 
TABLE NO. 10 
 
PREPARATION OF WORKING STANDARDS FOR IRON: 
 
Working Standard 
Concentration  
(µg/dL) 
Stock Solution 
mL 
Deionised water 
mL 
50 0.05 9.95 
100 0.10 9.90 
200 0.20 9.80 
300 0.30 9.70 
400 0.40 9.60 
 
 
 
 
 
 
TABLE NO.14 
 
REFERENCE INTERVAL FOR SERUM TRANSFERRIN 
 
Serum reference intervals based on CRM 47079 are as follows. 
 
Age g/L mg/dL 
Newborn 1.17 – 2.50 117 – 250 
Adults (20 – 60 yr) 2.0 – 3.6 200 – 360 
> 60 yr 1.6 – 3.4 160 – 340 
  
 
 
 
TABLE NO. 15 
 
PREPARATION OF WORKING STANDARDS FOR ZINC 
 
Working Standard 
(µg / dL) 
Available Zinc 
Concentration 
(200µg/dL) 
(µL) 
Deionised Water  
                (µL) 
50 25 75 
100 25 25 
 
 
 
 
 
TABLE NO. 18 
 
PREPARATION OF WORKING STANDARDS FOR COPPER 
 
Working Standard 
Concentration  
(µg/dL) 
Stock Solution 
(mL) 
Deionised Water 
(mL) 
50 0.5 99.5 
100 1 99 
200 2 98 
300 3 97 
400 4 96 
 
FIGURE NO. 4 
 
SCHEMATIC REPRESENTATION OF THE SUBUNIT  
STRUCTURE OF FERRITIN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced from Harrison PM, Arosio P. The  Ferritin: Molecular properties,       
iron storage function and cellular regulation, Biochim Biophys Acta 
1996;1275:161- 203 
FIGURE NO.1 
INCIDENCE RATES OF TREATED END-STAGE RENAL DISEASE 
(ESRD) PER MILLION POPULATION FROM 1982 TO 1991 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Reproduced from United States Renal Data System, 1995. Annual Data Report, 
U.S. Department of Health and Human Services, Health Care Financing 
Administration.
 
FIGURE NO.3 
ABSORPTION OF IRON IN THE GASTROINTESTINAL TRACT 
 
 
 
  
Reproduced from Ganong WF: Review of Medical Physiology, 2003, 21st edition, 
Page No.482. McGraw-Hill. 
                                                
FIGURE NO. 5 
 
STRUCTURE AND FUNCTIONAL SITES IN HUMAN 
CERULOPLASMIN
 
 
Binding and Active Sites 
Pro-oxidant: A              Copper: F, G, H  
Peroxidase: B             NO: I,J  
Amine: C                        Fe3+: K 
LSD: D                        Fe2+I: E  
REPRODUCED FROM WEBSITE: E:\ caeruloplasmin structure – function pdb 
file display. htm. 
 FIGURE NO. 2 
 
  SCHEMA FOR HEMODIALYSIS 
 
Reproduced from Charles D. Carpenter and J. Michael Lazarus. Dialysis and 
Transplantation in the treatment of renal failure. Harrison’s Principle and Practice 
of Internal Medicine 1998, 14th edition Volume II, Page No. 1522. 
Mc Graw – Hill. 
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PROFORMA 
Stanley Medical College Hospital    Date : 
Chennai. 
 
Name   :      OP/IP  No: 
Age    : 
Sex   :  
Occupation  : 
Clinical History : 
 
On Examination   
Height:                                              Weight:  
Heart rate:                                         Blood Pressure:            Respiratory rate: 
Cardiovascular system:                     Respiratory System: 
Central Nervous System:                  Abdomen: 
Investigation:   
1. Blood Urea     :     
2. Serum Creatinine    : 
3. Serum Iron     : 
4. Serum Total Iron Binding Capacity : 
5. Serum Ferritin    : 
6. Serum Transferrin Saturation  : 
7. Serum Transferrin    :   
8. Serum Copper    : 
9. Serum Ceruloplasmin   : 
10. Serum Zinc     : 
 
 
